Duloxetine
- Generic Name
- Duloxetine
- Brand Names
- Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19NOS
- CAS Number
- 116539-59-4
- Unique Ingredient Identifier
- O5TNM5N07U
- Background
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the tre...
- Indication
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
...
- Associated Conditions
- Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
- Associated Therapies
- -
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 60
- Registration Number
- NCT04245436
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Kristian Kjær Petersen
- Target Recruit Count
- 40
- Registration Number
- NCT04224584
- Locations
- 🇩🇰
Mech-Sense, Aalborg, Denmark
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Craig Rush
- Target Recruit Count
- 8
- Registration Number
- NCT04178993
- Locations
- 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 220
- Registration Number
- NCT04137107
- Locations
- 🇺🇸
The Hospital of Central Connecticut, New Britain, Connecticut, United States
🇺🇸Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
🇺🇸AdventHealth Kissimmee, Kissimmee, Florida, United States
Duloxetine Combined With Intra-articular Injection of Corticosteroid and Hyaluronic Acid Reduces Pain in the Treatment of Knee Osteoarthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04117893
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, Beijing, China
Exercise Plus Duloxetine for Knee Osteoarthritis
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 30
- Registration Number
- NCT04111627
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
Effects of Duloxetine on Postoperative Wound Complication of Total Knee Arthroplasty (TKA) in Central Sensitization Patients
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 80
- Registration Number
- NCT03880916
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Janssen-Cilag International NV
- Registration Number
- NCT03852160
A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression
- Conditions
- Interventions
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Yuqi Cheng
- Target Recruit Count
- 200
- Registration Number
- NCT03623711
- Locations
- 🇨🇳
The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Craig Rush
- Target Recruit Count
- 19
- Registration Number
- NCT03575403
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.